207 related articles for article (PubMed ID: 27091697)
1. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model.
Shrestha N; Araújo F; Shahbazi MA; Mäkilä E; Gomes MJ; Airavaara M; Kauppinen EI; Raula J; Salonen J; Hirvonen J; Sarmento B; Santos HA
J Control Release; 2016 Jun; 232():113-9. PubMed ID: 27091697
[TBL] [Abstract][Full Text] [Related]
2. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy.
Araújo F; Shrestha N; Gomes MJ; Herranz-Blanco B; Liu D; Hirvonen JJ; Granja PL; Santos HA; Sarmento B
Nanoscale; 2016 May; 8(20):10706-13. PubMed ID: 27150301
[TBL] [Abstract][Full Text] [Related]
3. Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system.
Shrestha N; Shahbazi MA; Araújo F; Mäkilä E; Raula J; Kauppinen EI; Salonen J; Sarmento B; Hirvonen J; Santos HA
Biomaterials; 2015 Nov; 68():9-20. PubMed ID: 26253804
[TBL] [Abstract][Full Text] [Related]
4. Microfluidic Assembly of a Multifunctional Tailorable Composite System Designed for Site Specific Combined Oral Delivery of Peptide Drugs.
Araújo F; Shrestha N; Shahbazi MA; Liu D; Herranz-Blanco B; Mäkilä EM; Salonen JJ; Hirvonen JT; Granja PL; Sarmento B; Santos HA
ACS Nano; 2015 Aug; 9(8):8291-302. PubMed ID: 26235314
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery.
Briere DA; Bueno AB; Gunn EJ; Michael MD; Sloop KW
Diabetes; 2018 Feb; 67(2):309-320. PubMed ID: 29203510
[TBL] [Abstract][Full Text] [Related]
6. Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes.
Jean M; Alameh M; De Jesus D; Thibault M; Lavertu M; Darras V; Nelea M; Buschmann MD; Merzouki A
Eur J Pharm Sci; 2012 Jan; 45(1-2):138-49. PubMed ID: 22085632
[TBL] [Abstract][Full Text] [Related]
7. Constitutive increase in active GLP-1 levels by the DPP4 inhibitor ASP4000 on a new meal tolerance test in Zucker fatty rats.
Tanaka-Amino K; Hatakeyama Y; Takakura S; Mutoh S
Pharmacol Res; 2009 Oct; 60(4):264-9. PubMed ID: 19520592
[TBL] [Abstract][Full Text] [Related]
8. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
[TBL] [Abstract][Full Text] [Related]
9. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
10. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
12. Update on incretin hormones.
Phillips LK; Prins JB
Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
[TBL] [Abstract][Full Text] [Related]
13. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Moritoh Y; Takeuchi K; Hazama M
J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
16. Novel strategy for oral peptide delivery in incretin-based diabetes treatment.
Xu Y; Van Hul M; Suriano F; Préat V; Cani PD; Beloqui A
Gut; 2020 May; 69(5):911-919. PubMed ID: 31401561
[TBL] [Abstract][Full Text] [Related]
17. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Pharmacol Rep; 2009; 61(5):899-908. PubMed ID: 19904014
[TBL] [Abstract][Full Text] [Related]
18. A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice.
Lu Y; Lu P; Wang Y; Fang X; Wu J; Wang X
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646613
[TBL] [Abstract][Full Text] [Related]
19. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Mulvihill EE
Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
